According to filings with the U.S. Securities and Exchange Commission, Upkara is raising $12,150,000.00 in new funding. Sources indicate that as part of senior management President, Pravansu Mohanty played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Upkara
Upkara aims to eliminate the cold chain requirements of therapeutics, vaccines and reagents with its innovative, patented, biopreservation technology. The preservation, storage and distribution of therapeutics, vaccines and reagents is expensive and complicated, and the cold chain requirements continue to grow. As the industry focuses on sophisticated biologics and gene-based therapies, the development of temperature-sensitive therapeutics is out pacing other products. Our anhydrobiotic vitrification technology eliminates the need for temperature control. The rapid stabilization process preserves products in a proprietary medium, protecting them from temperature extremes of up to 55C (131F). The breakthrough enables biologics, vaccines, nucleic acids, blood products, and others, to be stored at ambient and varying temperatures without impact on function. The Upkara technology eliminates reliance on cold chain storage and distribution.

To learn more about Upkara, visit http://upkara.com/

Contact:
Pravansu Mohanty, President
734-215-5345

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.